Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability

NCT04945278 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-05-31
Last updated
2026-03-19

Condition(s) studied

Psychosis of Childhood BorderlinePsychotic Disorder

Investigational drug(s) / intervention(s)

Double mirror device ALTER-EGOEASE test

Double mirror device ALTER-EGO: The patient and his matched healthy volunteer will be placed on each side of the double mirror device ALTER-EGO. Both sides will be lightened alternatively or at the same time by lights, so according to the light intensity, the subject will see himself in a mirror or the other person throw a classic window. The light intensity will vary from 0 to 100% and to 100% to 0% alternatively from each side of the mirror. At each 10% variation of one side, both patient and volunteer will have to answer that question : "who do you see more : him/her or yourself ?"

EASE test: The patient will have to answer the EASE test which is a specific test to detect patient with high risk of psychosis or schizophrenia

Study summary

The main objective of this study is to establish whether there are differences in self-recognition and self/other distinction in subjects with psychological vulnerability compared to healthy volunteer controls.

Eligibility

Sex
ALL
Min age
15 Years
Max age
25 Years
Healthy volunteers
Accepted
Inclusion criteria for patients: * Aged from 15 to 25 years * Subject meeting the Ultra High Risk criteria at CAARMS and / or SPI-A * Signature of the consent (participants and parents for minors) * Subject affiliated to the social security scheme or benefiting from such a scheme Inclusion criteria for healthy volunteers: * Aged from 15 to 25 years * Subject not familiar to the patient to whom it is matched * Signature of the consent (participants and parents for minors) * Subject affiliated to the social security scheme or benefiting from such a scheme Exclusion Criteria for both patients and healthy volunteers: * History of epilepsy and / or migraine (due to the epileptogenic potential of light stimuli) * Refusal of participation of the minor even if the legal representatives want the subject to participate in the study * Claustrophobia * Wearing glasses * Abnormal right and left visual acuity without contact lenses * Distinctive signs on the face which cannot be temporarily removed * Subject under legal protection (curators / guardianship) or deprived of liberty

Primary outcome measure(s)

  • Average of the three M1 — Inclusion
    Average of the three M1 thresholds obtained from the "round trip" manipulation repeated three times, the M1 threshold corresponding to the level of luminosity from which a subject begins to recognize himself when his own image gradually appears (during the passage of the condition glass in mirror condition).

Trial sites (1)

FacilityCityRegionStatus
CHRU BREST Hôpital de Bohars Bohars France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04945278 on ClinicalTrials.gov ↗ ← All trials in France